Drugs / Tetraspan
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00847977 | Oct 2008 → Oct 2010 | traumatic brain injury | Nantes University Hospital | Terminated | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01418521 | Aug 2011 → Jul 2013 | — | Rambam Health Care Campus | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01729364 | Apr 2008 → Dec 2014 | impaired renal function disease | Sahlgrenska University Hospital | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TETRASPAN | “Both solutions are crystalloids who received MA in France for ISOFUNDINE, MA in Germany with pending MA in France for TETRASPAN, including an indication for infusion.” NCT00847977 ↗3“Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.” NCT01418521 ↗ “Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes” NCT00847977 ↗ “Tetraspan” NCT01729364 ↗ |
| Modality | Other / unclassified | “3rd generation HES (Hydroxyethyl Starch) solution - Tetraspan®” NCT01418521 ↗ |